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AbstrAct:
Netrin-1 (NTN1) is functionally important for the development of the nervous system. 
Interestingly, few recent studies showed that NTN1 may also promote cancer by 
increasing survival and resistance of lung and breast cancer cells to apoptosis. Our 
purpose was to investigate whether NTN1 and its receptor DCC may be involved 
in ovarian cancer. The NTN1 and DCC  mRNAs  were  quantified  by  real-time  RT-
PCR in normal (10), benign (8) and cancer (17) ovarian tissues. ALAS1 and TBP 
housekeeping genes were used for normalization. NTN1 was found overexpressed in 
76% of ovarian cancer specimens (13/17) as compared to normal (0/10, p<0.004) 
and benign (1/8, p<0.008) samples. Increased NTN1 mRNA levels correlated with 
advanced tumor stage (stage III, n=8, 100%) and grade (grade 3, n=7, 100%). In 
contrast, DCC was found downregulated in 59% (10/17) of ovarian tumors tested but 
correlation was not significant when compared to normal or benign specimens. Here, 
we demonstrated that NTN1 may be involved in ovarian cancer as the expression of 
NTN1 mRNA is strongly upregulated in ovarian malignant tumors but not in benign 
tumors. The fact that increased NTN1 is specifically observed in cancerous tissues 
indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.
IntroductIon
Netrin-1 (NTN1) is a diffusible laminin-related 
protein that has been shown to play a major role in 
the control of neural navigation in the developing 
nervous system [1, 2]. Recently, NTN1 was proposed 
to play crucial roles in tumorigenesis as it is involved in 
regulation of apoptosis by binding to DCC and UNC5H 
family of dependence receptors that share the ability to 
induce apoptosis in the absence of their ligands, a trait 
that confers tumor suppressor activity on these receptors 
[3]. Expression of one of these dependence receptors 
at the surface of a tumor cell is considered to render 
it dependent on ligand availability for survival, thus, 
inhibiting uncontrolled tumor cell proliferation and/
or metastasis. Accumulating evidence implies that this 
positive signaling pathway is frequently inactivated 
in human cancers, as it was shown that expression of 
DCC and UNC5H is lost during tumor progression, 
thus, conferring a selective advantage to the tumor cell 
for survival [3]. In addition, this model predicts that a 
similar advantage may be obtained by gaining autocrine 
expression of the NTN1 ligand in tumor cells. Indeed, a 
high percentage of colorectal [4] and metastatic breast [5] 
cancers overexpress NTN1. 
Binding of NTN1 to its receptors inhibits p53-
dependent apoptosis, while p53 is directly involved in 
transcriptional regulation of NTN1 and its receptors [3]. 
Thus, NTN1 expression confers resistance to apoptosis, 
thus, enhancing tumor cell survival. In non-small cell 
lung cancer (NSCLC), >50% of the analyzed tissue 
specimens expressed abnormally high levels of NTN1 
[6, 7]. Interestingly, a recent study revealed that NTN1 
expression is selectively up-regulated in colorectal 
cancers associated with bowel diseases. Moreover, it was 
demonstrated  that  this  inflammation-driven  NTN1 up-
regulation is causal for colorectal cancer development, 
as interference with the NTN1 autocrine loop inhibited Oncotarget 2011; 2:  363 - 367 364 www.impactjournals.com/oncotarget
colorectal cancer progression without affecting 
inflammation  in  a  mouse  model  for  ulcerative  colitis-
associated colorectal cancer [4]. 
In this direction, it was shown recently that autocrine 
production of NTN1 in aggressive neuroblastomas conveys 
selective advantage for tumor growth and dissemination 
[8], as it blocks the pro-apoptotic activity of the NTN1 
receptors, UNC5H, leading to resistance to apoptosis 
that is a prerequisite for neuroblastoma progression. 
NTN1 up-regulation was suggested as a potential marker 
for poor prognosis in infants diagnosed with stage 4S 
neuroblastoma [8]. It was proposed that interference with 
the NTN1 autocrine loop in malignant neuroblasts may 
represent an alternative therapeutic strategy, as it was 
shown that disruption of this loop triggers cell death and 
inhibits metastasis of neuroblastoma in avian and mouse 
models [8]. 
Interestingly, NTN1 was proposed to play an important 
role in embryonic and pathological angiogenesis acting as 
a survival factor also for endothelial cells by blocking the 
pro-apoptotic effect of the dependence receptor UNC5B 
and its downstream death-signaling effector, the serine/
threonine kinase DAPK. Thus, the proapoptotic effect 
of unbound UNC5B and the survival effect of NTN1 
on  endothelial  cells  finely  tune  the  angiogenic  process 
[9]. Nonetheless, in a recent study, NTN1 was found 
strongly up-regulated in pancreatic adenocarcinomas and 
this aberrant NTN1 overexpression was associated with 
resistance to apoptosis for both tumor and endothelial 
cells [10]. Triggered by these recent studies pinpointing to 
important roles of NTN1 in most common malignancies, 
we investigated here whether NTN1 expression changes 
between normal, benign and cancerous ovarian tissues. 
In addition, we examined the expression of the NTN1 
receptor DCC. It must be noted that DCC is considered 
a tumor suppressor that was originally identified based 
on allelic deletions at 18q21 associated with colorectal 
cancer [11].
results And dIscussIon
As shown in Figure 1 and Table 1, strong 
upregulation of NTN1 expression was detected in the 
majority of ovarian cancer specimens when compared to 
normal (p<0.004) or benign (p<0.008) which is significant 
according to the T-test values. Expression was considered 
high when the ratio NTN1/reporter genes (ALAS1-TBP) 
was ≥6 and for DCC/reporter genes (ALAS1-TBP) ≥0.1. 
More importantly, upregulation of NTN1 mRNA correlated 
well with advanced stage of disease (p<0.005, Mann-
Whitney U test). It should be noted that a larger cohort 
of samples should be analyzed, in order to interrogate 
whether NTN1 expression can be used to predict disease-
free survival and/or overall survival. Contrary, DCC was 
found downregulated in 10/17 (59%) cancer specimens, 
which is well in accordance with previous observations 
that reported decreased DCC in 55% of ovarian cancers 
when measured by immunohistochemistry and RT-PCR in 
a much larger number of patients [14, 15]. Interestingy, 
re-expression of DCC in ovarian cancer cells induced an 
apoptosis phenotype [15]. DCC deactivation results from 
loss-of-heterozygosity in a subset of ovarian cancers [16]. 
We were unable to correlate the decreased DCC expression 
to tumor grade or stage probably due to the small number 
of samples analyzed. Nonetheless, it should be noted that 
7/17 cancer specimens exhibited high DCC expression 
which correlated with NTN1 upregulation in 6/7 samples 
(p<0.098 Pearson correlation). Expression of DCC in this 
subset of ovarian cancers is counterbalanced by increased 
NTN1 levels, thus, again leading to evasion of apoptosis. 
Figure 1: ntn1 and dcc mrnA expression in ovarian samples. Relative expression levels of NTN1 (left) and DCC (right) 
were analyzed in the clinical samples. Changes between benign-normal and cancer-normal are considered significant with both the T-test 
and Mann-Whitney U test (shown are p values calculated by the T-test).
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When all 35 samples (normal, benign and cancer) were 
included in the analysis, no correlation (p<0.519) was 
derived between NTN1 and DCC expression. 
In summary, we show here for the first time that 
NTN1  is aberrantly overexpressed in the vast majority 
of malignant ovarian tumors but not in benign tumors. 
Moreover, high NTN1 expression correlates well with 
both tumor stage and grade. The observed alteration in 
NTN1 expression upon progression to malignancy can 
safely be considered significant as it pertained to 100% 
of malignant tumors, while in normal and benign tissues 
NTN1 was barely expressed. Lack of expression in normal/
benign is a desired but rare feature of cancer biomarkers. 
Our finding that NTN1 expression can possibly be used as 
a biomarker to distinguish benign from malignant ovarian 
tumors, also implies that NTN1 may be implicated in 
the progression of benign disease to malignancy. Our 
improved understanding of the mechanisms underlying 
the key emergent property of cancers, their malignancy, is 
expected to promote our efforts to reduce cancer mortality 
[17]. Based on the intriguing finding that NTN1 expression 
is not altered in benign ovarian tumors, we propose that 
NTN1 expression should be evaluated in prospective 
studies as a promising candidate biomarker to distinguish 
benign from malignant tumors of the ovary. 
PAtIents And Methods
clinical samples
All clinical samples used in this study were collected 
at the University of Turin, Italy. Tissues were obtained 
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NTN1 DCC 
   cases high 
expression 
low
expression 
p value high 
expression 
low 
expression 
p value 
Normal    10  0/10 (0%)  10/10 
(100%) 
  6/10 (60%)  4/10 (40%)   
    Age  ≥54  4  0/4 (0%)  4/4 (100%)    3/4 (75%)  1/4 (25%)   
  <54  6  0/6 (0%)  6/6 (100%)    3/6 (50%)  3/6 (50%)   
Benign    8  1/8 (12.5)  7/8 (87.5)    5/8 (62.5%)  3/8 (37.5%)   
  relative to normal  0.231      0.829 
    Age  ≥54  2  0/2 (0%)  2/2 (100%)    1/2 (50%)  1/2 (50%)   
  <54  6  1/6 (17%)  5/6 (83%)    4/6 (67%)  2/6 (33%)   
Tumor   17  13/17 
(76%) 
4/17 (24%)    7/17 (41%)  10/17 
(59%) 
  
  relative to normal  0.004
*     0.675 
relative to benign   0.008
*     0.977 
    Age  ≥54  10  8/10 (80%)  2/10 (20%)    5/10 (50%)  5/10 (50%)   
  <54  7  4/7 (57%)  3/7 (43%)    2/7 (28.6%)  5/7 (71.4%)   
Grade  0  1  1/1 (100%)  0/1 (0%)    1/1 (100%)  0/1 (0%)   
  1  1  0/1 (0%)  1/1 (100%)    1/1 (100%)  0/1 (0%)   
  2  5  3/5 (60%)  2/5 (40%)    1/5 (20%)  4/5 (80%)   
  3  7  7/7 (100%)  0/7 (0%)    4/7 (57%)  3/7 (43%)   
  relative to grade ≤2 0.013
**   0.414 
  U  3  2/3 (67%)  1/3 (33%)    0/3 (0%)  3/3 (100%)   
Stage  I  5  2/5 (40%)  3/5 (60%)    1/5 (20%)  4/5 (80%)   
  II  1  1/1 (100%)  0/1 (0%)    1/1 (100%)  0/1 (0%)   
  III  8  8/8 (100%)  0/8 (0%)     5/8 (62.5%)  3/8 (37.5%)    
  relative to stage ≤2 0.005
**   0.805 
  U  3  2/3 (67%)  1/3 (33%)    0/3 (0%)  3/3 (100%)   
High expression is considered the ratio NTN1/reporter genes (ALAS1-TBP) ≥ 6 and 
DCC/reporter genes (ALAS1-TBP) ≥ 0.1 
U: Unknown characteristics 
*statistically significant, T-test values 
**statistically significant, Mann-Whitney U test 
 
 
table 1: clinicopathological features for patient samples correlated to NTN1 and DCC expression in ovarian tissue 
specimens.Oncotarget 2011; 2:  363 - 367 366 www.impactjournals.com/oncotarget
following informed and signed consent of the patient 
under a general tissue collection protocol approved by the 
Institutional Review Board and the University of Turin, 
Italy. The samples were snap-frozen in liquid nitrogen and 
stored at -80oC. 
rnA extraction
RNA extraction was performed with RNeasy 
(Qiagen) after tissue pulverization with a pestle and 
mortar under liquid nitrogen. RNA purity and integrity 
were  confirmed  by  spectrophotometry  and  agarose  gel 
electrophoresis, respectively. 
reverse transcription and Quantitative Pcr
500 ng of total RNA were reverse-transcribed with 
Superscript II (Invitrogen) using an oligo dT primer 
according to the standard protocol. The total volume 
of the recovered cDNA was 21 μl. Real-time PCR was 
carried out in 25 μl with SYBR Green (Invitrogen) in 
a  Rotor  Gene  3000  (Cobert  Research).  The  following 
conditions  were  applied  for  PCR  amplification:  50oC 
for 2 min, 94oC for 5 min followed by 45 cycles (40 for 
ALAS1, TBP) of 94oC for 15 sec, 54oC for 20 sec (54oC 
for 30 sec for ALAS1, TBP), and 72oC for 20 sec (30 sec 
for ALAS1, TBP). The sequences of NTN1 primers were: 
5’-TGC AAG AAG GAC TAT GCC GT-3’ and 5’-GCT 
CGT GCC CTG CTT ATA CAC-3’ and for DCC were: 
AGC CAA TGG GAA AAT TAC TGC TTA C and AGG 
TTG AGA TCC ATG ATT TGA TGA G [8]. ALAS1 and 
TBP primer sets for real-time PCR were obtained from 
Qiagen (QuantiTect Primer Assay). Serial dilutions 
of cDNAs from selected tissue samples were used to 
determine  the  amplification  efficiency  of  NTN1,  DCC, 
ALAS1 and TBP. The Pfaffl model [12] and the REST 
2009© relative expression software tool [13] were used 
to  determine  the  amplification  efficiency  and  estimate 
the relative changes in mRNA levels of NTN1 and DCC. 
Data normalization was carried out against both ALAS1 
and TBP1 housekeeping genes, for improved reliability of 
results. Efficiency and fold-change were calculated based 
on cycle-threshold values using the REST software and 
ALAS1 and TBP1 as controls. All samples were analyzed 
in triplicates in two independent experiments. 
classical rt-Pcr and sequencing
Finally, semiquantitative conventional RT-PCR was 
performed with OneStep (Qiagen) and the PCR products 
were resolved by agarose gel electrophoresis (not shown). 
Two randomly selected products were gel-extracted 
(Qiagen) and sequenced using the NTN1-specific forward 
primer (VBC, Austria), in order to verify that the PCR 
product was indeed NTN1-specific. 
statistical analysis
The Mann-Whitney U test or T-test were used to 
correlate clinical parameters (stage, grade) and NTN1 
or  DCC relative mRNA expression levels. Statistical 
analyses were performed with SPSS (SPSS® release 15.0, 
Chicago, IL, USA).
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